Table 2.
Chronic Graft-versus-Host disease characteristics
| Chronic GvHD characteristics at time of onset of cGvHD (n = 22) | All | Resolved cGvHD (n = 11), n (%) | Active cGvHD (n = 11), n (%) | p-value |
|---|---|---|---|---|
| Median days from transplantation to onset of cGvHD (IQR) | 326 (208, 601) | 350 (224, 595) | 240 (151, 723) | 1.0 |
| Subcategories of cGvHD type at time of onset | ||||
| Classic cGvHD | 20 (90.9%) | 10 (90.9%) | 10 (90.9%) | 1.0 |
| Overlap cGvHD | 2 (9.1%) | 1 (9.1%) | 1 (9.1%) | |
| NIH severity of cGvHD at maximum severity | ||||
| Mild | 2 (9.1%) | 1 (9.1%) | 1 (9.1%) | .080 |
| Moderate | 11 (50.0%) | 8 (72.7%) | 3 (27.3%) | |
| Severe | 9 (40.9%) | 2 (18.2%) | 7 (63.6%) | |
| Organ manifestations of cGvHD at maximum severity | ||||
| Cutaneous | 16 (72.7%) | 8 (72.7%) | 8 (72.7%) | 1.0 |
| Oral | 13 (59.1%) | 5 (45.5%) | 8 (72.7%) | .387 |
| Eye | 9 (40.9%) | 4 (36.4%) | 5 (45.5%) | 1.0 |
| Lung | 5 (22.7%) | 3 (27.3%) | 2 (18.2%) | 1.0 |
| Gastrointestinal | 4 (18.2%) | 3 (27.3%) | 1 (9.1%) | .586 |
| Liver | 4 (18.2%) | – | 4 (36.4%) | .090 |
| Vaginal | 4 (18.2%) | 2 (18.2%) | 2 (18.2%) | 1.0 |
| Fascia | 2 (9.1%) | – | 2 (18.2%) | .476 |
| Joint | 2 (9.1%) | 1 (9.1%) | 1 (9.1%) | 1.0 |
| Platelet count at cGvHD onset, thrombocytes/µl | ||||
| Median (IQR) | 224 (90, 325) | 240 (90, 306) | 175 (77, 387) | 1.0 |
| Platelet count at cGvHD onset | ||||
| < 100/nL | 6 (27.3%) | 3 (27.3%) | 3 (27.3%) | 1.0 |
| ≥ 100/nL | 16 (72.7%) | 8 (72.7%) | 8 (72.7%) | |
Data presented are n (%) unless otherwise indicated
cGvHD: chronic Graft-versus-Host disease; Resolved cGvHD: all signs of clinically activity of cGvHD have disappeared, past history of cGvHD, no immunosuppression; Active cGvHD: physician reported inflammatory manifestations of cGvHD; IQR: interquartile range; NIH: National Institutes of Health